Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Brad Kahl
Washington University, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Abbvie
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Based on Washington University’s Research COI Policy and the Procedures for Determining and Managing Research Financial Conflicts of Interests, Washington University determined Dr. Brad Kahl’s personal financial relationship with Abbvie related to the above referenced research creates a financial conflict of interest due to the following reasons:
• Dr. Kahl’s personal financial relationship is directly related to the research because the study is evaluating a product owned by AbbVie (Venetoclax) which is the primary topic of his advisory board service.
• Dr. Kalh’s role, as described below, could directly affect the study.
While the committee determined financial conflicts of interest exist, they concluded sufficient mechanisms exist to ensure the objectivity and integrity of the research, based on the following reasons:
• This is a multicenter (100 sites) randomized study and WU is not the coordinating site. WU is only expected to enroll 30 out of 720 total patients.
• Dr. Kahl is not involved in research design
• The entity is a large publicly traded company
• Additionally, a plan has been developed to mitigate Dr. Kahl’s financial conflict of interest, which is outlined below.
Washington University/Siteman Cancer Center Lead Academic Site
Project Narrative SCC is the only NCI-designated Comprehensive Cancer Center in Missouri and Southern Illinois and it is the leading oncology treatment facility within the St. Louis metropolitan area. Participation in the NCTN allows WU/SCC physicians to offer a broad range of clinical trials to patients with all types and stages of cancer and also provides an opportunity for investigators to confirm preliminary institutional findings regarding new cancer treatments, diagnostic tools, and prognostic markers in large numbers of patients.
Filed on June 20, 2019.
Tell us what you know about Brad Kahl's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.